2型炎症在未控制持续性哮喘治疗中的关键问题
本综述总结了哮喘2型炎症的生物学机制及其对共病的影响,指出2型炎症由固有免疫与适应性免疫共同驱动,以IL-4、IL-5、IL-13上调及IgE介导的免疫介质释放为特征。靶向这些近端2型细胞因子的生物制剂在个体化治疗中已显示疗效,FeNO、血清IgE及血和痰嗜酸性粒细胞等下游生物标志物有助于诊断、预测和监测治疗反应。
要点
- 2型炎症涉及固有免疫与适应性免疫,以IL-4、IL-5、IL-13上调为核心特征。
- 靶向近端2型细胞因子的生物制剂在个体化治疗中已显示疗效。
- FeNO、血清IgE及血和痰嗜酸性粒细胞等生物标志物可辅助诊断与监测治疗反应。
核心结论
- 2型炎症是未控制持续性哮喘慢性炎症复杂病理生理及共病的重要基础,靶向近端2型细胞因子的生物制剂个体化治疗已显示疗效。
研究设计与样本
- 综述,总结当前对哮喘2型炎症生物学的认识、其对2型炎症共病的影响及生物标志物在生物制剂时代个体化治疗中的应用。
主要发现
- 2型炎症由固有免疫(2型固有淋巴细胞)与适应性免疫(2型辅助T细胞)共同参与,以IL-4、IL-5、IL-13上调、IgE介导的免疫介质释放及上皮或表皮屏障功能障碍为特征。
- 2型炎症与慢性鼻窦炎伴鼻息肉、过敏性鼻炎和特应性皮炎等共病相关。
- 靶向近端2型细胞因子的生物制剂在采用个体化治疗的研究中已显示疗效。
- FeNO、血清IgE及血和痰嗜酸性粒细胞等2型细胞因子下游生物标志物升高与2型炎症相关机制有关,有潜力辅助诊断、预测和监测治疗反应。
临床怎么用
- 可依据2型炎症生物标志物(FeNO、血清IgE及血和痰嗜酸性粒细胞)辅助诊断、预测和监测哮喘治疗反应。
- 在生物制剂治疗时代,可针对近端2型细胞因子进行个体化治疗选择。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Asthma is a complex respiratory disease that varies in severity and response to treatment. Several asthma phenotypes with unique clinical and inflammatory characteristics have been identified. Endotypes, based on distinct molecular profiles, help to further elucidate the heterogeneity within asthma. Type 2 inflammation, involving both the innate (type 2 innate lymphoid cell) and adaptive (T-helper type 2 cells) immune systems, underpins the complex pathophysiology of chronic inflammation in asthma, as well as the presence of comorbid disease (e.g. chronic rhinosinusitis with nasal polyps, allergic rhinitis and atopic dermatitis). Type 2 inflammation is characterised by upregulation of the type 2 cytokines interleukin (IL)-4, IL-5 and IL-13, IgE-mediated release of immune mediators and dysfunction of epithelial or epidermal barriers. Targeting these key proximal type 2 cytokines has shown efficacy in recent studies adopting a personalised approach to treatment using targeted biologics. Elevated levels of biomarkers downstream of type 2 cytokines, including fractional exhaled nitric oxide, serum IgE and blood and sputum eosinophils, have been linked to mechanisms involved in type 2 inflammation. They have the potential to aid diagnosis, and to predict and monitor response to treatment. The objective of this review is to summarise the current understanding of the biology of type 2 inflammation in asthma, examine its influence on type 2 inflammatory comorbidities, and discuss how type 2 inflammatory biomarkers can be harnessed to further personalise treatments in the age of biologic medicines.
引用
- Busse WW, Kraft M, Rabe KF, et al. Understanding the key issues in the treatment of uncontrolled persistent asthma with type 2 inflammation. Eur Respir J. 2021. PMID: 33542055. doi:10.1183/13993003.03393-2020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。